Related Experiment Videos
Neoadjuvant hormone therapy: the Canadian trials
L Klotz1, M Gleave, S L Goldenberg
1Sunnybrook Health Science Center, University of Toronto, Toronto, Ontario, Canada. Laurence.klotz@utoronto.ca
Molecular Urology
|November 4, 2000
Summary
Neoadjuvant hormonal therapy (NHT) in prostate cancer shows mixed results. While one study improved biochemical progression, another found no significant difference. Longer treatment durations improved pathological outcomes in a recent trial.
Area of Science:
- Urologic Oncology
- Medical Oncology
- Prostate Cancer Research
Background:
- The Canadian Urologic Oncology Group has investigated neoadjuvant hormonal therapy (NHT) for prostate cancer.
- Previous studies explored cyproterone acetate (CPA) efficacy with mixed outcomes.
Purpose of the Study:
- To evaluate the efficacy of different durations of NHT prior to radical prostatectomy.
- To assess the impact of NHT on biochemical progression, pathological findings, and potentially survival.
Main Methods:
- A randomized trial compared 3 versus 8 months of leuprolide plus flutamide before prostatectomy.
- Patient stratification was based on clinical stage, Gleason grade, and PSA levels.
- Pathological outcomes including positive margin and organ-confined rates were analyzed.
Main Results:
- Extended NHT (8 months) significantly improved presurgery PSA levels (<0.1 ng/mL in 73% vs 35%) and reduced positive margin rates (5% vs 17%).
- Organ-confined disease rates were substantially higher with 8 months of NHT (91% vs 71%, P < 0.01).
- Biochemical progression rates were similar in a previous study comparing 3 months of CPA to surgery alone.
Conclusions:
- Longer neoadjuvant hormonal therapy (8 months) significantly enhances pathological outcomes in prostate cancer patients undergoing radical prostatectomy.
- Further data on long-term progression and survival are necessary to confirm clinical benefit.
- The findings support optimizing NHT duration for improved surgical results in prostate cancer management.